肾血管平滑肌脂肪瘤的治疗进展  

Progress in Treatment of Renal Angiomyolipoma

作　　者：杨恩广 景锁世 范光锐 高硕泽 刘伟[1] 王志平[1] YANG En-guang;JING Suo-shi;FAN Guang-rui;GAO Shuo-ze;LIU Wei;WANG Zhi-ping(Institute of Urological Diseases,Second Hospital Affiliated to Lanzhou University,Gansu Provincial Key Laboratory of Urological Diseases,Gansu Provincial Urology Center,Lanzhou 730030,Chin;First Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院泌尿系疾病研究所甘肃省泌尿系疾病研究重点实验室甘肃省泌尿系统疾病临床医学中心,甘肃兰州730030 [2]兰州大学第一医院,甘肃兰州730030

出　　处：《中国肿瘤》2018年第10期790-795,共6页China Cancer

基　　金：国家自然科学基金项目(81672519)

摘　　要：肾血管平滑肌脂肪瘤（renal angiomyolipoma,RAML）作为一种常见的肾良性肿瘤,有多种治疗方式,包括保守治疗、药物治疗、微创介入治疗（消融术、肾动脉栓塞术）以及手术治疗（肾切除术和保留肾单位手术）,均有良好疗效。近年来新的技术理念层出不穷,大于4cm肿瘤不主张早期干预,雷帕霉素靶蛋白（m TOR）抑制剂治疗结节硬化症（tuberous sclerosis,TS）取得显著效果,手术治疗新技术不断发展,微创介入治疗适应证更加宽泛,本文就以上进展进行综述以期指导临床。Renal angiomyolipoma（RAML） is a common benign neoplasm,which can be managed with conservative treatment,drug therapy,minimally invasive interventional therapy（ablation,renal artery embolization）,and surgical treatments（nephrectomies and nephron-sparing surgery）.This article reviews the recent progresses of new therapeutic ideas and modalities for RAML ：there is no need of early intervention for tumors larger than 4 cm;the m TOR inhibitors are effective for tuberous sclerosis（TS）;the newly developed surgical techniques are available;and the indications for minimally invasive interventions are broadened and so on.

关 键 词：肾血管平滑肌脂肪瘤 结节硬化症 治疗 

分 类 号：R737.11[医药卫生—肿瘤]